HEADER TRANSFERASE/TRANSFERASE INHIBITOR 14-NOV-13 4NLD
TITLE CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS5B RNA-DEPENDENT RNA
TITLE 2 POLYMERASE COMPLEX WITH BMS-791325 ALSO KNOWN AS (1AR,12BS)-8-
TITLE 3 CYCLOHEXYL-N-(DIMETHYLSULFAMOYL)-11-METHOXY-1A-{[(1R,5S)-3-METHYL-3,
TITLE 4 8-DIAZABICYCLO[3.2.1]OCT-8-YL]CARBONYL}-1,1A,2,12B-
TITLE 5 TETRAHYDROCYCLOPROPA[D]INDOLO[2,1-A][2]BENZAZEPINE-5-CARBOXAMIDE AND
TITLE 6 2-(4-FLUOROPHENYL)-N-METHYL-6-[(METHYLSULFONYL)AMINO]-5-(PROPAN-2-
TITLE 7 YLOXY)-1-BENZOFURAN-3-CARBOXAMIDE
COMPND MOL_ID: 1;
COMPND 2 MOLECULE: RNA-DIRECTED RNA POLYMERASE;
COMPND 3 CHAIN: A;
COMPND 4 FRAGMENT: UNP RESIDUES 2420-2992;
COMPND 5 SYNONYM: NS5B, P68;
COMPND 6 EC: 2.7.7.48;
COMPND 7 ENGINEERED: YES
SOURCE MOL_ID: 1;
SOURCE 2 ORGANISM_SCIENTIFIC: HEPATITIS C VIRUS;
SOURCE 3 ORGANISM_COMMON: HCV;
SOURCE 4 ORGANISM_TAXID: 333284;
SOURCE 5 STRAIN: BARTENSCHLAGER;
SOURCE 6 GENE: NS5B;
SOURCE 7 EXPRESSION_SYSTEM: ESCHERICHIA COLI;
SOURCE 8 EXPRESSION_SYSTEM_TAXID: 469008;
SOURCE 9 EXPRESSION_SYSTEM_STRAIN: BL21(DE3) STAR;
SOURCE 10 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID;
SOURCE 11 EXPRESSION_SYSTEM_PLASMID: PET21B
KEYWDS NS5B, POLYMERASE, HCV, HEPATITIS C VIRUS, FINGERS, PALM, THUMB,
KEYWDS 2 TRANSFERASE/TRANSFERASE INHIBITOR, POLYMERASE/POLYMERASE INHIBITOR,
KEYWDS 3 TRANSFERASE-TRANSFERASE INHIBITOR COMPLEX
EXPDTA X-RAY DIFFRACTION
AUTHOR S.SHERIFF
REVDAT 5 03-APR-24 4NLD 1 REMARK
REVDAT 4 28-FEB-24 4NLD 1 HETSYN
REVDAT 3 29-JUL-20 4NLD 1 COMPND REMARK SEQADV HETNAM
REVDAT 3 2 1 SITE
REVDAT 2 26-MAR-14 4NLD 1 JRNL
REVDAT 1 19-MAR-14 4NLD 0
JRNL AUTH R.G.GENTLES,M.DING,J.A.BENDER,C.P.BERGSTROM,K.GRANT-YOUNG,
JRNL AUTH 2 P.HEWAWASAM,T.HUDYMA,S.MARTIN,A.NICKEL,A.REGUEIRO-REN,Y.TU,
JRNL AUTH 3 Z.YANG,K.S.YEUNG,X.ZHENG,S.CHAO,J.H.SUN,B.R.BENO,D.M.CAMAC,
JRNL AUTH 4 C.H.CHANG,M.GAO,P.E.MORIN,S.SHERIFF,J.TREDUP,J.WAN,
JRNL AUTH 5 M.R.WITMER,D.XIE,U.HANUMEGOWDA,J.KNIPE,K.MOSURE,K.S.SANTONE,
JRNL AUTH 6 D.D.PARKER,X.ZHUO,J.LEMM,M.LIU,L.PELOSI,K.RIGAT,S.VOSS,
JRNL AUTH 7 Y.WANG,Y.K.WANG,R.J.COLONNO,M.GAO,S.B.ROBERTS,Q.GAO,A.NG,
JRNL AUTH 8 N.A.MEANWELL,J.F.KADOW
JRNL TITL DISCOVERY AND PRECLINICAL CHARACTERIZATION OF THE
JRNL TITL 2 CYCLOPROPYLINDOLOBENZAZEPINE BMS-791325, A POTENT ALLOSTERIC
JRNL TITL 3 INHIBITOR OF THE HEPATITIS C VIRUS NS5B POLYMERASE.
JRNL REF J.MED.CHEM. V. 57 1855 2014
JRNL REFN ISSN 0022-2623
JRNL PMID 24397558
JRNL DOI 10.1021/JM4016894
REMARK 2
REMARK 2 RESOLUTION. 2.75 ANGSTROMS.
REMARK 3
REMARK 3 REFINEMENT.
REMARK 3 PROGRAM : BUSTER-TNT BUSTER 2.11.4
REMARK 3 AUTHORS : BRICOGNE,BLANC,BRANDL,FLENSBURG,KELLER,
REMARK 3 : PACIOREK,ROVERSI,SHARFF,SMART,VONRHEIN,
REMARK 3 : WOMACK,MATTHEWS,TEN EYCK,TRONRUD
REMARK 3
REMARK 3 DATA USED IN REFINEMENT.
REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.75
REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 39.42
REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000
REMARK 3 COMPLETENESS FOR RANGE (%) : 92.4
REMARK 3 NUMBER OF REFLECTIONS : 21785
REMARK 3
REMARK 3 FIT TO DATA USED IN REFINEMENT.
REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT
REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM
REMARK 3 R VALUE (WORKING + TEST SET) : 0.215
REMARK 3 R VALUE (WORKING SET) : 0.213
REMARK 3 FREE R VALUE : 0.253
REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.730
REMARK 3 FREE R VALUE TEST SET COUNT : 1030
REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL
REMARK 3
REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN.
REMARK 3 TOTAL NUMBER OF BINS USED : 11
REMARK 3 BIN RESOLUTION RANGE HIGH (ANGSTROMS) : 2.75
REMARK 3 BIN RESOLUTION RANGE LOW (ANGSTROMS) : 2.88
REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 92.38
REMARK 3 REFLECTIONS IN BIN (WORKING + TEST SET) : 2928
REMARK 3 BIN R VALUE (WORKING + TEST SET) : 0.2453
REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 2796
REMARK 3 BIN R VALUE (WORKING SET) : 0.2444
REMARK 3 BIN FREE R VALUE : 0.2637
REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.51
REMARK 3 BIN FREE R VALUE TEST SET COUNT : 132
REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL
REMARK 3
REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT.
REMARK 3 PROTEIN ATOMS : 3867
REMARK 3 NUCLEIC ACID ATOMS : 0
REMARK 3 HETEROGEN ATOMS : 136
REMARK 3 SOLVENT ATOMS : 31
REMARK 3
REMARK 3 B VALUES.
REMARK 3 FROM WILSON PLOT (A**2) : 72.05
REMARK 3 MEAN B VALUE (OVERALL, A**2) : 61.27
REMARK 3 OVERALL ANISOTROPIC B VALUE.
REMARK 3 B11 (A**2) : 4.82020
REMARK 3 B22 (A**2) : -12.76960
REMARK 3 B33 (A**2) : 7.94930
REMARK 3 B12 (A**2) : 0.00000
REMARK 3 B13 (A**2) : 0.00000
REMARK 3 B23 (A**2) : 0.00000
REMARK 3
REMARK 3 ESTIMATED COORDINATE ERROR.
REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.402
REMARK 3 DPI (BLOW EQ-10) BASED ON R VALUE (A) : 0.498
REMARK 3 DPI (BLOW EQ-9) BASED ON FREE R VALUE (A) : 0.302
REMARK 3 DPI (CRUICKSHANK) BASED ON R VALUE (A) : 0.518
REMARK 3 DPI (CRUICKSHANK) BASED ON FREE R VALUE (A) : 0.306
REMARK 3
REMARK 3 REFERENCES: BLOW, D. (2002) ACTA CRYST D58, 792-797
REMARK 3 CRUICKSHANK, D.W.J. (1999) ACTA CRYST D55, 583-601
REMARK 3
REMARK 3 CORRELATION COEFFICIENTS.
REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.924
REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.901
REMARK 3
REMARK 3 NUMBER OF GEOMETRIC FUNCTION TERMS DEFINED : 15
REMARK 3 TERM COUNT WEIGHT FUNCTION.
REMARK 3 BOND LENGTHS : 4158 ; 2.000 ; HARMONIC
REMARK 3 BOND ANGLES : 5716 ; 2.000 ; HARMONIC
REMARK 3 TORSION ANGLES : 1431 ; 2.000 ; SINUSOIDAL
REMARK 3 TRIGONAL CARBON PLANES : 76 ; 2.000 ; HARMONIC
REMARK 3 GENERAL PLANES : 658 ; 5.000 ; HARMONIC
REMARK 3 ISOTROPIC THERMAL FACTORS : 4158 ; 20.000 ; HARMONIC
REMARK 3 BAD NON-BONDED CONTACTS : NULL ; NULL ; NULL
REMARK 3 IMPROPER TORSIONS : NULL ; NULL ; NULL
REMARK 3 PSEUDOROTATION ANGLES : NULL ; NULL ; NULL
REMARK 3 CHIRAL IMPROPER TORSION : 536 ; 5.000 ; SEMIHARMONIC
REMARK 3 SUM OF OCCUPANCIES : NULL ; NULL ; NULL
REMARK 3 UTILITY DISTANCES : NULL ; NULL ; NULL
REMARK 3 UTILITY ANGLES : NULL ; NULL ; NULL
REMARK 3 UTILITY TORSION : NULL ; NULL ; NULL
REMARK 3 IDEAL-DIST CONTACT TERM : 4708 ; 4.000 ; SEMIHARMONIC
REMARK 3
REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES.
REMARK 3 BOND LENGTHS (A) : 0.009
REMARK 3 BOND ANGLES (DEGREES) : 1.07
REMARK 3 PEPTIDE OMEGA TORSION ANGLES (DEGREES) : 2.89
REMARK 3 OTHER TORSION ANGLES (DEGREES) : 18.81
REMARK 3
REMARK 3 TLS DETAILS
REMARK 3 NUMBER OF TLS GROUPS : NULL
REMARK 3
REMARK 3 OTHER REFINEMENT REMARKS: NULL
REMARK 4
REMARK 4 4NLD COMPLIES WITH FORMAT V. 3.30, 13-JUL-11
REMARK 100
REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 09-DEC-13.
REMARK 100 THE DEPOSITION ID IS D_1000083348.
REMARK 200
REMARK 200 EXPERIMENTAL DETAILS
REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION
REMARK 200 DATE OF DATA COLLECTION : 10-NOV-06
REMARK 200 TEMPERATURE (KELVIN) : 100.0
REMARK 200 PH : 5.6
REMARK 200 NUMBER OF CRYSTALS USED : 1
REMARK 200
REMARK 200 SYNCHROTRON (Y/N) : Y
REMARK 200 RADIATION SOURCE : APS
REMARK 200 BEAMLINE : 17-ID
REMARK 200 X-RAY GENERATOR MODEL : NULL
REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M
REMARK 200 WAVELENGTH OR RANGE (A) : 1.0
REMARK 200 MONOCHROMATOR : NULL
REMARK 200 OPTICS : NULL
REMARK 200
REMARK 200 DETECTOR TYPE : CCD
REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 210
REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 (DENZO)
REMARK 200 DATA SCALING SOFTWARE : HKL-2000 (SCALEPACK)
REMARK 200
REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 22091
REMARK 200 RESOLUTION RANGE HIGH (A) : 2.750
REMARK 200 RESOLUTION RANGE LOW (A) : 50.000
REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000
REMARK 200
REMARK 200 OVERALL.
REMARK 200 COMPLETENESS FOR RANGE (%) : 93.0
REMARK 200 DATA REDUNDANCY : 5.500
REMARK 200 R MERGE (I) : 0.08100
REMARK 200 R SYM (I) : NULL
REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 18.3000
REMARK 200
REMARK 200 IN THE HIGHEST RESOLUTION SHELL.
REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.75
REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.85
REMARK 200 COMPLETENESS FOR SHELL (%) : 94.7
REMARK 200 DATA REDUNDANCY IN SHELL : 5.50
REMARK 200 R MERGE FOR SHELL (I) : 0.49900
REMARK 200 R SYM FOR SHELL (I) : NULL
REMARK 200 <I/SIGMA(I)> FOR SHELL : 3.200
REMARK 200
REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH
REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT
REMARK 200 SOFTWARE USED: AMORE
REMARK 200 STARTING MODEL: NS5B/LIGAND COMPLEX
REMARK 200
REMARK 200 REMARK: NULL
REMARK 280
REMARK 280 CRYSTAL
REMARK 280 SOLVENT CONTENT, VS (%): 64.52
REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.47
REMARK 280
REMARK 280 CRYSTALLIZATION CONDITIONS: 100 MM SODIUM CITRATE, 1.75 M
REMARK 280 (NH4)2SO4, PH 5.6, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE
REMARK 280 293K
REMARK 290
REMARK 290 CRYSTALLOGRAPHIC SYMMETRY
REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: I 2 2 2
REMARK 290
REMARK 290 SYMOP SYMMETRY
REMARK 290 NNNMMM OPERATOR
REMARK 290 1555 X,Y,Z
REMARK 290 2555 -X,-Y,Z
REMARK 290 3555 -X,Y,-Z
REMARK 290 4555 X,-Y,-Z
REMARK 290 5555 X+1/2,Y+1/2,Z+1/2
REMARK 290 6555 -X+1/2,-Y+1/2,Z+1/2
REMARK 290 7555 -X+1/2,Y+1/2,-Z+1/2
REMARK 290 8555 X+1/2,-Y+1/2,-Z+1/2
REMARK 290
REMARK 290 WHERE NNN -> OPERATOR NUMBER
REMARK 290 MMM -> TRANSLATION VECTOR
REMARK 290
REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS
REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM
REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY
REMARK 290 RELATED MOLECULES.
REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000
REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000
REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000
REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000
REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000
REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000
REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000
REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 0.00000
REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 0.00000
REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 0.00000
REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000
REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000
REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 36.50000
REMARK 290 SMTRY2 5 0.000000 1.000000 0.000000 60.30000
REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 100.75000
REMARK 290 SMTRY1 6 -1.000000 0.000000 0.000000 36.50000
REMARK 290 SMTRY2 6 0.000000 -1.000000 0.000000 60.30000
REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 100.75000
REMARK 290 SMTRY1 7 -1.000000 0.000000 0.000000 36.50000
REMARK 290 SMTRY2 7 0.000000 1.000000 0.000000 60.30000
REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 100.75000
REMARK 290 SMTRY1 8 1.000000 0.000000 0.000000 36.50000
REMARK 290 SMTRY2 8 0.000000 -1.000000 0.000000 60.30000
REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 100.75000
REMARK 290
REMARK 290 REMARK: NULL
REMARK 300
REMARK 300 BIOMOLECULE: 1
REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM
REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN
REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON
REMARK 300 BURIED SURFACE AREA.
REMARK 350
REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN
REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE
REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS
REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND
REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN.
REMARK 350
REMARK 350 BIOMOLECULE: 1
REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC
REMARK 350 APPLY THE FOLLOWING TO CHAINS: A
REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000
REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000
REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000
REMARK 465
REMARK 465 MISSING RESIDUES
REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE
REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN
REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.)
REMARK 465
REMARK 465 M RES C SSSEQI
REMARK 465 MET A 0
REMARK 465 SER A 1
REMARK 465 MET A 2
REMARK 465 SER A 3
REMARK 465 TYR A 4
REMARK 465 THR A 5
REMARK 465 TRP A 6
REMARK 465 THR A 7
REMARK 465 GLY A 8
REMARK 465 ALA A 9
REMARK 465 LEU A 10
REMARK 465 ILE A 11
REMARK 465 THR A 12
REMARK 465 PRO A 13
REMARK 465 CYS A 14
REMARK 465 ALA A 15
REMARK 465 ALA A 16
REMARK 465 GLU A 17
REMARK 465 GLU A 18
REMARK 465 THR A 19
REMARK 465 LYS A 20
REMARK 465 LEU A 21
REMARK 465 PRO A 22
REMARK 465 ILE A 23
REMARK 465 ASN A 24
REMARK 465 ALA A 25
REMARK 465 LEU A 26
REMARK 465 SER A 27
REMARK 465 ASN A 28
REMARK 465 SER A 29
REMARK 465 LEU A 30
REMARK 465 LEU A 31
REMARK 465 ARG A 32
REMARK 465 HIS A 33
REMARK 465 HIS A 34
REMARK 465 ASN A 35
REMARK 465 LEU A 36
REMARK 465 VAL A 37
REMARK 465 TYR A 38
REMARK 465 ALA A 39
REMARK 465 THR A 40
REMARK 465 THR A 41
REMARK 465 SER A 42
REMARK 465 ARG A 43
REMARK 465 SER A 44
REMARK 465 ALA A 45
REMARK 465 SER A 46
REMARK 465 LEU A 47
REMARK 465 ARG A 48
REMARK 465 GLN A 49
REMARK 465 LYS A 50
REMARK 465 LYS A 51
REMARK 465 VAL A 52
REMARK 465 THR A 53
REMARK 465 SER A 269
REMARK 465 LYS A 270
REMARK 465 GLY A 271
REMARK 465 GLN A 272
REMARK 465 ASN A 273
REMARK 465 ASP A 559
REMARK 465 ILE A 560
REMARK 465 TYR A 561
REMARK 465 HIS A 562
REMARK 465 SER A 563
REMARK 465 LEU A 564
REMARK 465 SER A 565
REMARK 465 ARG A 566
REMARK 465 ALA A 567
REMARK 465 ARG A 568
REMARK 465 PRO A 569
REMARK 465 ARG A 570
REMARK 465 TRP A 571
REMARK 465 PHE A 572
REMARK 465 MET A 573
REMARK 470
REMARK 470 MISSING ATOM
REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER;
REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER;
REMARK 470 I=INSERTION CODE):
REMARK 470 M RES CSSEQI ATOMS
REMARK 470 LEU A 57 CG CD1 CD2
REMARK 470 LYS A 114 CG CD CE NZ
REMARK 470 GLU A 131 CG CD OE1 OE2
REMARK 470 LYS A 355 CD CE NZ
REMARK 470 ARG A 531 CD NE CZ NH1 NH2
REMARK 470 GLN A 544 CG CD OE1 NE2
REMARK 500
REMARK 500 GEOMETRY AND STEREOCHEMISTRY
REMARK 500 SUBTOPIC: TORSION ANGLES
REMARK 500
REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS:
REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER;
REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE).
REMARK 500
REMARK 500 STANDARD TABLE:
REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2)
REMARK 500
REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI-
REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400
REMARK 500
REMARK 500 M RES CSSEQI PSI PHI
REMARK 500 ASP A 55 -125.24 46.03
REMARK 500 ALA A 105 154.77 60.68
REMARK 500 LYS A 106 -60.16 74.48
REMARK 500 LEU A 111 126.61 59.82
REMARK 500 GLU A 131 -31.55 -130.22
REMARK 500 PHE A 145 58.27 -92.29
REMARK 500 THR A 181 -40.51 -132.43
REMARK 500 LEU A 260 -58.38 -128.59
REMARK 500 ILE A 424 -61.94 -101.43
REMARK 500 TYR A 448 -107.87 59.36
REMARK 500 LEU A 536 94.18 77.30
REMARK 500
REMARK 500 REMARK: NULL
DBREF 4NLD A 1 573 UNP Q9WMX2 POLG_HCVCO 2420 2992
SEQADV 4NLD MET A 0 UNP Q9WMX2 EXPRESSION TAG
SEQRES 1 A 574 MET SER MET SER TYR THR TRP THR GLY ALA LEU ILE THR
SEQRES 2 A 574 PRO CYS ALA ALA GLU GLU THR LYS LEU PRO ILE ASN ALA
SEQRES 3 A 574 LEU SER ASN SER LEU LEU ARG HIS HIS ASN LEU VAL TYR
SEQRES 4 A 574 ALA THR THR SER ARG SER ALA SER LEU ARG GLN LYS LYS
SEQRES 5 A 574 VAL THR PHE ASP ARG LEU GLN VAL LEU ASP ASP HIS TYR
SEQRES 6 A 574 ARG ASP VAL LEU LYS GLU MET LYS ALA LYS ALA SER THR
SEQRES 7 A 574 VAL LYS ALA LYS LEU LEU SER VAL GLU GLU ALA CYS LYS
SEQRES 8 A 574 LEU THR PRO PRO HIS SER ALA ARG SER LYS PHE GLY TYR
SEQRES 9 A 574 GLY ALA LYS ASP VAL ARG ASN LEU SER SER LYS ALA VAL
SEQRES 10 A 574 ASN HIS ILE ARG SER VAL TRP LYS ASP LEU LEU GLU ASP
SEQRES 11 A 574 THR GLU THR PRO ILE ASP THR THR ILE MET ALA LYS ASN
SEQRES 12 A 574 GLU VAL PHE CYS VAL GLN PRO GLU LYS GLY GLY ARG LYS
SEQRES 13 A 574 PRO ALA ARG LEU ILE VAL PHE PRO ASP LEU GLY VAL ARG
SEQRES 14 A 574 VAL CYS GLU LYS MET ALA LEU TYR ASP VAL VAL SER THR
SEQRES 15 A 574 LEU PRO GLN ALA VAL MET GLY SER SER TYR GLY PHE GLN
SEQRES 16 A 574 TYR SER PRO GLY GLN ARG VAL GLU PHE LEU VAL ASN ALA
SEQRES 17 A 574 TRP LYS ALA LYS LYS CYS PRO MET GLY PHE ALA TYR ASP
SEQRES 18 A 574 THR ARG CYS PHE ASP SER THR VAL THR GLU ASN ASP ILE
SEQRES 19 A 574 ARG VAL GLU GLU SER ILE TYR GLN CYS CYS ASP LEU ALA
SEQRES 20 A 574 PRO GLU ALA ARG GLN ALA ILE ARG SER LEU THR GLU ARG
SEQRES 21 A 574 LEU TYR ILE GLY GLY PRO LEU THR ASN SER LYS GLY GLN
SEQRES 22 A 574 ASN CYS GLY TYR ARG ARG CYS ARG ALA SER GLY VAL LEU
SEQRES 23 A 574 THR THR SER CYS GLY ASN THR LEU THR CYS TYR LEU LYS
SEQRES 24 A 574 ALA ALA ALA ALA CYS ARG ALA ALA LYS LEU GLN ASP CYS
SEQRES 25 A 574 THR MET LEU VAL CYS GLY ASP ASP LEU VAL VAL ILE CYS
SEQRES 26 A 574 GLU SER ALA GLY THR GLN GLU ASP GLU ALA SER LEU ARG
SEQRES 27 A 574 ALA PHE THR GLU ALA MET THR ARG TYR SER ALA PRO PRO
SEQRES 28 A 574 GLY ASP PRO PRO LYS PRO GLU TYR ASP LEU GLU LEU ILE
SEQRES 29 A 574 THR SER CYS SER SER ASN VAL SER VAL ALA HIS ASP ALA
SEQRES 30 A 574 SER GLY LYS ARG VAL TYR TYR LEU THR ARG ASP PRO THR
SEQRES 31 A 574 THR PRO LEU ALA ARG ALA ALA TRP GLU THR ALA ARG HIS
SEQRES 32 A 574 THR PRO VAL ASN SER TRP LEU GLY ASN ILE ILE MET TYR
SEQRES 33 A 574 ALA PRO THR LEU TRP ALA ARG MET ILE LEU MET THR HIS
SEQRES 34 A 574 PHE PHE SER ILE LEU LEU ALA GLN GLU GLN LEU GLU LYS
SEQRES 35 A 574 ALA LEU ASP CYS GLN ILE TYR GLY ALA CYS TYR SER ILE
SEQRES 36 A 574 GLU PRO LEU ASP LEU PRO GLN ILE ILE GLN ARG LEU HIS
SEQRES 37 A 574 GLY LEU SER ALA PHE SER LEU HIS SER TYR SER PRO GLY
SEQRES 38 A 574 GLU ILE ASN ARG VAL ALA SER CYS LEU ARG LYS LEU GLY
SEQRES 39 A 574 VAL PRO PRO LEU ARG VAL TRP ARG HIS ARG ALA ARG SER
SEQRES 40 A 574 VAL ARG ALA ARG LEU LEU SER GLN GLY GLY ARG ALA ALA
SEQRES 41 A 574 THR CYS GLY LYS TYR LEU PHE ASN TRP ALA VAL ARG THR
SEQRES 42 A 574 LYS LEU LYS LEU THR PRO ILE PRO ALA ALA SER GLN LEU
SEQRES 43 A 574 ASP LEU SER SER TRP PHE VAL ALA GLY TYR SER GLY GLY
SEQRES 44 A 574 ASP ILE TYR HIS SER LEU SER ARG ALA ARG PRO ARG TRP
SEQRES 45 A 574 PHE MET
HET 2N7 A 601 92
HET 2N5 A 602 50
HET SO4 A 603 5
HET SO4 A 604 5
HET SO4 A 605 5
HET SO4 A 606 5
HET BOG A 607 20
HET BOG A 608 20
HETNAM 2N7 (1AR,12BS)-8-CYCLOHEXYL-N-(DIMETHYLSULFAMOYL)-11-
HETNAM 2 2N7 METHOXY-1A-{[(1R,5S)-3-METHYL-3,8-
HETNAM 3 2N7 DIAZABICYCLO[3.2.1]OCT-8-YL]CARBONYL}-1,1A,2,12B-
HETNAM 4 2N7 TETRAHYDROCYCLOPROPA[D]INDOLO[2,1-A][2]BENZAZEPINE-5-
HETNAM 5 2N7 CARBOXAMIDE
HETNAM 2N5 2-(4-FLUOROPHENYL)-N-METHYL-6-[(METHYLSULFONYL)AMINO]-
HETNAM 2 2N5 5-(PROPAN-2-YLOXY)-1-BENZOFURAN-3-CARBOXAMIDE
HETNAM SO4 SULFATE ION
HETNAM BOG OCTYL BETA-D-GLUCOPYRANOSIDE
HETSYN BOG BETA-OCTYLGLUCOSIDE; OCTYL BETA-D-GLUCOSIDE; OCTYL D-
HETSYN 2 BOG GLUCOSIDE; OCTYL GLUCOSIDE
FORMUL 2 2N7 C36 H45 N5 O5 S
FORMUL 3 2N5 C20 H21 F N2 O5 S
FORMUL 4 SO4 4(O4 S 2-)
FORMUL 8 BOG 2(C14 H28 O6)
FORMUL 10 HOH *31(H2 O)
HELIX 1 1 ASP A 61 SER A 76 1 16
HELIX 2 2 SER A 84 LEU A 91 1 8
HELIX 3 3 SER A 112 ASP A 129 1 18
HELIX 4 4 ASP A 164 SER A 180 1 17
HELIX 5 5 THR A 181 GLY A 188 1 8
HELIX 6 6 SER A 189 TYR A 195 5 7
HELIX 7 7 SER A 196 LYS A 211 1 16
HELIX 8 8 THR A 229 GLN A 241 1 13
HELIX 9 9 ALA A 246 LEU A 260 1 15
HELIX 10 10 GLY A 283 ALA A 306 1 24
HELIX 11 11 GLY A 328 TYR A 346 1 19
HELIX 12 12 ASP A 359 ILE A 363 5 5
HELIX 13 13 PRO A 388 ARG A 401 1 14
HELIX 14 14 ASN A 406 ALA A 416 1 11
HELIX 15 15 THR A 418 ILE A 424 1 7
HELIX 16 16 ILE A 424 GLU A 437 1 14
HELIX 17 17 GLU A 455 LEU A 457 5 3
HELIX 18 18 ASP A 458 GLY A 468 1 11
HELIX 19 19 LEU A 469 SER A 473 5 5
HELIX 20 20 SER A 478 GLY A 493 1 16
HELIX 21 21 PRO A 496 GLN A 514 1 19
HELIX 22 22 GLY A 515 PHE A 526 1 12
HELIX 23 23 ASN A 527 VAL A 530 5 4
HELIX 24 24 ALA A 541 ASP A 546 1 6
HELIX 25 25 SER A 548 VAL A 552 5 5
SHEET 1 A 4 ALA A 157 PRO A 163 0
SHEET 2 A 4 THR A 136 ASN A 142 -1 N LYS A 141 O ARG A 158
SHEET 3 A 4 GLY A 264 THR A 267 1 O THR A 267 N THR A 136
SHEET 4 A 4 TYR A 276 ARG A 277 -1 O ARG A 277 N GLY A 264
SHEET 1 B 3 PRO A 214 ASP A 220 0
SHEET 2 B 3 ASP A 319 GLU A 325 -1 O CYS A 324 N MET A 215
SHEET 3 B 3 GLN A 309 CYS A 316 -1 N CYS A 316 O ASP A 319
SHEET 1 C 2 ASN A 369 HIS A 374 0
SHEET 2 C 2 ARG A 380 THR A 385 -1 O VAL A 381 N ALA A 373
SHEET 1 D 2 LEU A 443 GLN A 446 0
SHEET 2 D 2 CYS A 451 ILE A 454 -1 O ILE A 454 N LEU A 443
CRYST1 73.000 120.600 201.500 90.00 90.00 90.00 I 2 2 2 8
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 0.013699 0.000000 0.000000 0.00000
SCALE2 0.000000 0.008292 0.000000 0.00000
SCALE3 0.000000 0.000000 0.004963 0.00000